Mesoblast Ltd Secures BLA Filing Number and Seeks Modular FDA Review
Mesoblast secures BLA filing number and requests modular FDA review for heart failure therapy
Mesoblast (ASX:MSB; Nasdaq:MESO) has received a Biologics License Application (BLA) filing number from the U.S. Food and Drug Administration (FDA) and has requested a modular review of its BLA for rexlemestrocel-L. The submission targets the prevention of life-threatening gastrointestinal bleeding due to right ventricular dysfunction in end-stage heart failure patients with a left ventricular assist device (LVAD).
The therapy already holds two key FDA designations for this patient population. These are Orphan Drug Designation (for prevention of life-threatening major mucosal bleeding events) and Regenerative Medicine Advanced Therapy (RMAT) designation.
Crucially for investors, both designations provide eligibility for rolling and priority reviews of the BLA. This shapes a potentially faster regulatory pathway for a rare-disease therapy addressing a population with high mortality.
When big ASX news breaks, our subscribers know first
What the modular review and FDA flexibility mean for the pathway
Mesoblast noted that new FDA leadership recently provided additional guidance on how it approaches regulatory flexibility for products addressing orphan rare diseases with high mortality and irreversible morbidity.
Two recent FDA documents are cited as supportive context. The June 2026 draft guidance titled “Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products” highlights the agency’s flexible approach to substantial evidence of effectiveness. This follows the May 2026 guidance titled “Chemistry, Manufacturing, and Controls Flexibilities for Developing Human Cellular and Gene Therapy Products for a Biologics License Application.”
These developments form supportive regulatory context, but do not imply that approval has been granted or is guaranteed.
CEO Commentary
“We look forward to working closely with FDA to make rexlemestrocel-L available for the end-stage heart failure patients on mechanical devices who are at high risk of developing life-threatening gastrointestinal bleeding caused by progressive right heart failure,” said Dr. Silviu Itescu, Chief Executive of Mesoblast.
Understanding the disease and the unmet need
Chronic heart failure (CHF) is characterised by poor heart function, resulting in insufficient blood flow to the body’s vital organs and extremities. Patients are commonly graded using the New York Heart Association (NYHA) classification, which ranges from Class I (mild, with no physical limitations) through to Class IV (severe or end-stage, where symptoms occur even at rest).
For the most advanced patients, an LVAD is a mechanical pump implanted to help the heart circulate blood. While life-prolonging, these devices are associated with an elevated risk of gastrointestinal bleeding linked to progressive right heart failure, the precise complication the therapy aims to address.
The scale of the affected population underpins the commercial opportunity. Key epidemiology figures from the announcement include:
-
CHF affects approximately 6.5 million people in the United States and 26 million globally.
-
Mortality approaches 50% at 5 years as patients progress beyond NYHA early Class II disease.
-
Over 100,000 US patients progress to end-stage HFrEF each year, with one-year mortality as high as 50%.
-
More than 2,500 life-prolonging LVADs are implanted in the US annually, of whom approximately 80% undergo the procedure as destination or permanent therapy.
About rexlemestrocel-L and the clinical foundation
Rexlemestrocel-L is an allogeneic preparation of immunoselected and culture-expanded mesenchymal precursor cells (MPC). It is being developed as an immunomodulatory therapy to address the high degree of inflammation in the heart and circulation present across the spectrum of heart failure and reduced ejection fraction (HFrEF) patients, from NYHA Class II through end-stage CHF.
The investigational therapy has been trialled in two large placebo-controlled randomised studies in patients with CHF.
| Trial population | Patient number | Trial design | Designation status |
|---|---|---|---|
| NYHA Class II/III HFrEF | 565 patients | Placebo-controlled randomised | – |
| End-stage HFrEF with LVAD | 159 patients | Placebo-controlled randomised | RMAT + Orphan Drug |
Rexlemestrocel-L holds FDA RMAT and Orphan Drug designations specifically for patients with end-stage HFrEF implanted with an LVAD.
The next major ASX story will hit our subscribers first
Why this milestone matters for investors
Mesoblast positions itself as a world leader in developing allogeneic (off-the-shelf) cellular medicines for severe and life-threatening inflammatory conditions. The company already has an approved commercial product in Ryoncil® (remestemcel-L-rknd), described as the first FDA-approved mesenchymal stromal cell (MSC) therapy, indicated for steroid-refractory acute graft versus host disease in paediatric patients 2 months and older.
Ryoncil real-world outcomes have reinforced the clinical trial data, with an 84% survival rate recorded across the first commercial patient cohort and reimbursement infrastructure now covering more than 260 million US lives following J-Code issuance in October 2025.
The broader pipeline and commercial footprint extend beyond cardiac applications:
-
Rexlemestrocel-L is also in development for chronic low back pain.
-
The company has established commercial partnerships in Japan, Europe and China.
-
Its intellectual property portfolio comprises over 1,000 granted patents or patent applications, with protection extending to at least 2044 in all major markets.
The next step centres on progressing the BLA through the modular review process. No PDUFA date or approval timeline has been disclosed, and the milestone represents a filing and review event rather than any form of regulatory approval. For investors, the receipt of a filing number alongside priority and rolling review eligibility marks a defined advance in the regulatory pathway for a therapy targeting a high-mortality, underserved patient population.
For investors exploring how Mesoblast intends to extend its competitive position beyond the current product generation, our deep-dive into Mesoblast’s CAR platform acquisition covers the exclusive worldwide Mayo Clinic license, the two near-term pipeline targets identified, and what the deal means for the company’s IP moat beyond 2044.
Don’t Miss the Next Healthcare Breakthrough on the ASX
Get FREE breaking ASX healthcare news delivered to your inbox within minutes of release, complete with in-depth analysis already done for you. Join 20,000+ investors who never miss a market-moving moment. Click the “Free Alerts” button at Big News Blast to start receiving alerts the moment ASX announcements drop.